GDF15 and cancer: As neoadjuvant or adjuvant immunotherapy becomes standard, the dual benefits of GDF-15 inhibition, including mitigating cancer cachexia and enhancing ICI immunocompetency, make this approach an attractive strategy alongside chemotherapy and/or immunotherapy.